Form 4: Entrada Therapeutics Director Mary Thistle Granted 19,000 Stock Options

Entrada Therapeutics, Inc. Director Mary Thistle was granted 19,000 stock options with an exercise price of $7.90, vesting on the earlier of June 11, 2026, or the next annual stockholders' meeting.

Summary

• Mary Thistle, a Director of Entrada Therapeutics, Inc. (TRDA), was granted 19,000 stock options.
• The options have an exercise price of $7.90 per share.
• The transaction date for the grant was June 11, 2025.
• The options are set to expire on June 11, 2035.
• Vesting will occur on the earlier of June 11, 2026 (one-year anniversary of the grant) or the Issuer's next annual meeting of stockholders.
• Following this transaction, Mary Thistle beneficially owns 19,000 derivative securities directly.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates continued alignment of a director's interests with shareholder value through equity compensation, which is a standard practice.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value only if the stock price increases above the exercise price.
• This is a common form of compensation for non-employee directors, indicating standard corporate governance practices.

Negatives

• No negative aspects are reported in this Form 4 filing, as it details an acquisition of options rather than a sale.

Risks

• The value of the granted options is subject to market fluctuations and the future performance of Entrada Therapeutics' stock.
• If the stock price does not exceed the exercise price of $7.90, the options may expire worthless.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholders, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• The granted stock options will vest on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders.

Key Dates

Keywords

Entrada Therapeutics, TRDA, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership